title: Frequency of pruritus in Plasmodium vivax malaria patients treated with chloroquine in Thailand.
abstract: Chloroquine-induced itch in black-skinned African malaria patients is common and frequently leads to poor compliance or treatment defaulting.To assess the frequency and severity of chloroquine-induced pruritus in an Asian population, we reviewed case records of 1189 Plasmodium vivax malaria patients treated with chloroquine (25 mg/kg over 3 days) at the Bangkok Hospital for Tropical Diseases from 1992 through 1997. The majority of patients were Thais or ethnic Burmese (light brown skin), referred from the western border of Thailand. Overall, there were 23 patients (1.9%) with complaints of pruritus during chloroquine therapy. Of these, 12 (52%) had palm and sole involvement, eight (35%) had generalized pruritus including the palms and soles, and three (13%) had palm itching only. One patient developed pruritus on the palms and soles on two consecutive admissions. The pruritus did not interfere with daily activity, was reduced in intensity by anti-histamine therapy, and did not affect the patient's willingness to complete the chloroquine regimen. Therapeutic responses in the 23 patients with chloroquine itch was similar to those without itch. Among the itch patients, there was no association with gender or level of parasitaemias. Our findings indicate that the frequency of chloroquine-induced pruritus in Asian patients treated with chloroquine for P. vivax malaria is low in comparison with black-skinned Africans.This may be related to pharmacogenetic factors, the infective Plasmodium species, drug metabolism or drug-parasite interactions, or a lower affinity of chloroquine for less pigmented skin.
authors.affiliation: Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
authors.forename: V
authors.initials: V
authors.lastname: Bussaratid
authors.forename: D S
authors.initials: DS
authors.lastname: Walsh
authors.forename: P
authors.initials: P
authors.lastname: Wilairatana
authors.forename: S
authors.initials: S
authors.lastname: Krudsood
authors.forename: U
authors.initials: U
authors.lastname: Silachamroon
authors.forename: S
authors.initials: S
authors.lastname: Looareesuwan
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000009:adverse effects*; D044466:Asian People; D002648:Child; D002738:Chloroquine / Q000009:adverse effects*; D003875:Drug Eruptions / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics; D005260:Female; D006801:Humans; D016780:Malaria, Vivax / Q000188:drug therapy*; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D010966:Plasmodium vivax / Q000302:isolation & purification; D015995:Prevalence; D011537:Pruritus / Q000139:chemically induced / Q000453:epidemiology* / Q000235:genetics; D012189:Retrospective Studies; D013785:Thailand / Q000453:epidemiology
chemical_list: D000962:Antimalarials; D002738:Chloroquine